SAN DIEGO & BEDMINSTER, N.J. – MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and...
Latest News
WASHINGTON – The Melanoma Research Alliance (MRA) released the following statements from MRA Chief Science Officer Marc Hurlbert, PhD and MRA President & CEO Michael Kaplan on the Food & Drug Administration approval of tebentafusp, the first drug for treating metastatic uveal melanoma: “This approval represents a new day for...
Sixteen-year-old Anthony Melena is an avid history buff. And a sports buff. And he loves to travel. So imagine the thrill he experienced in September when he went to Beijing, China, as part of an American delegation at the 2008 Paralympic Games. “I guess I was speechless (when I heard...
Milwaukee, WI – Kerry Hughes, President and Founder of Harmony 4 Hope (H4H), has been named the Mellowes Center’s Rare Disease Ambassador. Kerry has dedicated her career to elevating the voices of those affected by rare diseases, building impactful partnerships that align with our mission—translating genomic research into real-world advancements...
LAWRENCEVILLE, N.J. — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in...
San Diego, Calif. – About 90% of deaths from cancer are a result of metastasis — that is, from cancer’s ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain. And metastasis relies on cancer cells’ ability to...
POMEZIA, Italy – The Menarini Group announced today that additional data have been generated on SEL24/MEN1703, a first-in-class, orally available, dual PIM/FLT3 inhibitor, as part of the DIAMOND-01 trial. The results will be presented at both the upcoming American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) Virtual Congresses. DIAMOND-01...
FLORENCE, Italy – The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available, dual PIM/FLT3 inhibitor, in-licensed by Menarini from Ryvu Therapeutics, and currently investigated in...
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa. – Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on multiple myeloma (MM). This new CELLSEARCH® Circulating Multiple Myeloma Cells (CMMCs) Assay* captures...
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy HYPERION, third Phase 3 study to demonstrate significant efficacy in adults with PAH, was previously stopped early based on review of available data from clinical program...